

Profile of Japan Bioindustry Association

JBA

Charting a path for next-generation bio-industries

On June 11 of 2019, the government finalized what it calls *Bioeconomy Strategy 2019: Building Biocommunities which attract respect from both domestic and oversea people*. This strategy is positioned as an international strategy for creating businesses that use biotechnologies and sets forth four visions for society and nine market sectors to be realized.

Up until now, biotechnologies have coexisted with the life sciences and contributed to the growth of various industrial sectors, including pharmaceuticals, medical care, and healthcare; chemicals, materials, and energy; provisions, foodstuff, and primary industries; and the environment and life sector. Intended targets include fermentation, selective breeding, cell fusion, gene recombination, biomedicine, bio-pesticides, bio-chemicals, bioreactors, bioenergy, regenerative medicine, and gene diagnostics.

In recent years, however, various issues have emerged on a global scale, including those concerning food supplies, an aging society, health, illnesses, diseases, the environment, and resources. There are growing expectations that bio-industries will be able to significantly revolutionize these societal systems. For example, bio-industries that can help Japan, the world's biggest super-aging society, establish a society of health and longevity in which quality-of-life (QOL) standards are met will collectively constitute a model for international markets. For this reason, people would like to see a cross-fertilization of biotechnologies and digital sciences. In other words, our strategy is to shake up societal systems by having digital sciences serve as a go-between and bring individual heterogeneous bio-industries together. In a manner of speaking, we are talking about interactions between "cis" and "trans."

With a membership comprising representatives from the worlds of industry, government, and academia, the Japan Bioindustry Association is tasked with promoting innovations in the original areas of biotechnology that are unique to traditional Japan and helping establish industries that will contribute to systems harnessed by international society. Activities carried out by the Japan Bioindustry Association for the cultivation of both human resources and industries are expected to be key for the realization of these goals. I am committed to rendering service to the best of my abilities as the chairperson of this organization.



Dr. Keiko Abe
Chairperson,
Japan Bioindustry Association

JBA's 5 Actions

Policy Proposals and Dialogues

1

Promotion of bio-related policies

- Implementation of Japan's Bioeconomy strategy
- Policy dialogues (such as adaptation to Nagoya Protocol)

Advanced Biotechnology Agora

2

Discovery of Seeds/Commercialization

Cooperation of the government, industry, and academia

- Seminars for providing information on advanced biotechnology
- Study group activities
- R&D project design

Promotion of Open Innovation

3

Cooperation with companies, support of business ventures

- Business seminars
- Support of collaboration among bio-related parties

Global Networking and Framework Creation

4

Transmitting overseas biotechnology news and bio-related events

- Global cooperation-related seminars, BioJapan
- Members' communication

Bioindustry Infrastructure Establishment

5

Enhancement of working group activities

- Acceleration of new technology implementation
- Intellectual property committee activities
- Biotechnology human resources development
- Raising awareness of access to overseas genetic resources and benefit sharing

Overseas bio-organizations having agreements with JBA

Europe

- EU ● Austria ● Brussels (Belgium)
- Flanders (Belgium) ● Wallonia (Belgium)
- the Czech Republic ● Denmark ● Estonia
- Finland ● France ● Germany ● Ireland
- Lithuania ● the Netherlands ● Spain
- Catalonia (Spain) ● Sweden ● Switzerland
- UK ● Scotland (UK)
- Swiss Biotech Association (since 2005)
- Russian Biotechnology Society (since 2009)
- CLIB2021
(Bioclusters of the Rhein Region)/
Cluster Bioindustrielle
Biotechnologie (since 2009)
- DECHEMA (since 2010)
- Medicon Valley Alliance
(Denmark/Sweden) (since 2012)
- SwedenBIO (since 2013)
- Life Science Austria (since 2013)
- Eurasante (France) (since 2014)
- Biovalley France/Former Alsace Biovalley
(France) (since 2014)
- Enterprise Lithuania (Lithuania) (since 2015)
- ASEBIO (Spain) (since 2016)
- FlandersBio (Belgium) (since 2016)

Asia

- Hong Kong
- Malaysia
- Taiwan
- Shanghai Biopharmaceuticals
Industries Association
(since 2005)
- KoreaBIO (since 2012)
- Medical and Pharmaceutical
Commercial Association,
All-China Federation of Industry
and Commerce (since 2012)
- Taiwan Bio Industry Organization
(since 2012)
- New Taipei City Bio Technology
Alliance (since 2015)

Oceania

- Australia
- Queensland (Australia)
- Victoria (Australia)
- AusBiotech (since 2013)
- Life Sciences Queensland (since 2015)

Creation of International Network

JBA provides international information on biotechnology and bioindustry in cooperation with member companies, universities, and the government.

● JBA members (38 organizations as of September 2020)

● Overseas biotechnology organizations with which JBA has written agreements (as of September 2020)


Canada

- Canada
- Alberta
- British Columbia
- Ontario
- Quebec

United States

- US
- Florida
- Georgia
- Iowa
- North Carolina
- Michigan
- Pennsylvania
- BIO (since 2004)
- Biocom (since 2014)

Japanese bioclusters having relationship with JBA international network hub (All Japanese Bio Regions Committee)




Acceleration of Open Innovation


JBA provides opportunities to help the development of biotechnology and industry.

Asia's
No.1

Partnering
Event!



Exhibition



Partnering



Seminar



Medicine/Medical



Foods



Environment/
Energy



Diagnosis/
Medical devices



Health care



Research tools

Collaborative research
Licensing in and out
Business partnerships
Creating innovation in fusional areas



BioJapan



Regenerative
Medicine
Japan



JBA holds the partnering bio event BioJapan, the Regenerative Medicine Japan and the healthTECH JAPAN as key business platforms.

Implementation of Japan's Bioeconomy Strategy

The Japanese bioeconomy strategy, formulated in 2019 and revised in 2020, aims to establish the world's most advanced bioeconomy society in 2030, with "Bio-first concept", formation of "Bio-community", and "Bio data-driven". In detail, four social visions and nine market domains are set to achieve the strategy, and the expansion of each market domains are promoted with roadmaps that are updated every year. JBA, together

with JABEX, has promoted the activities of voluntary companies which shape roadmaps and present them to the Government. JBA/JABEX will contribute to the social implementation of the bioeconomy strategy through the participation of the revision and execution of the roadmaps in the strategy, the establishment of the bio-community area, the bio data linkage, and so on.

Social Visions and market domains determined by the Bioeconomy Strategy

Four social visions

Circular society that coordinates all industries

Society engaged in sustainable primary production able to satisfy diverse needs

Society that uses sustainable production methods to create biomaterials and bio-based components

Society in which medicine and non medical health care coordinate to enable long, active social participation

Nine market domains

- ① High-function bio-materials (lightweight, durable, safe)

② Bioplastic (general plastic substitutes)

③ Sustainable primary production system

④ Organic waste and organic wastewater treatment

⑤ Lifestyle improvement-focused healthcare, functional foods, and digital health

⑥ Related industry in bio pharmaceuticals, regenerative medicine, celluler treatment, and genetic treatment

⑦ Bio production system < Industry and food production related (production using biological functions)>

⑧ Bio-related analysis, measurement, and experiment systems

⑨ Large wooden structures and smart forestry

Support for Internal Bio-Venture Companies and Bio-Clusters

<div>Giving support to bio-ventures, and collaborative activities among bio-related parties</div> <div>Exchanges and cooperation among industry, academia and government are promoted through information exchanges and cooperative activities utilizing JBA's network linking biotechnology organizations and clusters all over Japan.</div>	<div>Conference of bio-related parties</div> <div>The conference considered the strengthening of the network linking the primary organizations for industry-government-academia cooperation in biotechnology in all the regions of Japan. It shares information among these organizations, and future guidelines, with the aim of establishing a system where these organizations cooperate closely.</div>	<div>Biocluster summit</div> <div>Biotechnology organizations from various countries gather in Japan to have deep discussions on the spirit of entrepreneurship, securing core human resources, and the importance of the formation of networks among companies and among entrepreneurs.</div>
---	--	--

About JBA

History

JBA's roots date back to Shusei Kyokai (the Distilled Spirits Institute) established in 1942.

Its name, after being changed to the Japanese Association of Industrial Fermentation, was renamed as Japan Bioindustry Association (JBA) in 1987.

Members

Corporate members: 279 companies (pharmaceutical, food, chemical, cosmetic and machinery companies)

Public members: 131 organizations

Individual members: approx. 600 (university and corporate researchers) (As of September 2020)

Board of Directors

Chairperson

Keiko Abe
Project Professor,
Graduate School of Agricultural and Life Sciences,
The University of Tokyo

President

Osamu Nagayama
Senior Advisor and Honorary Chairman,
Chugai Pharmaceutical Co., Ltd.

Executive Director

Yoshiaki Tsukamoto

Japan Bioindustry Association

Grande Bldg. 8F,
2-26-9 Hatchobori, Chuo-ku,
Tokyo 104-0032, Japan
Tel +81-3-5541-2731 Fax +81-3-5541-2737
URL <https://www.jba.or.jp/>

September 2020



Access

